NCT03498183View on ClinicalTrials.gov

Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

372

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

May 7, 2025

Study Completion Date

May 7, 2025

Conditions

Malignancy of Thyroid Nodules

Interventions

DRUG

MIBI-Tc99m/Iodine-123

Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.

Trial Locations (7)

59000

CHU, Lille

69000

Hospices Civils, Lyon

75005

Institut Curie, Paris

93000

hopital Avicenne, Bobigny

Unknown

CHU, Limoges

CHU, Nantes

75 000

Assistance publique des Hôpitaux de Paris, Paris

All Listed Sponsors

lead

Nantes University Hospital

OTHER

NCT03498183 - Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology | Biotech Hunter | Biotech Hunter